How many clinical trials are tracked for GERD?

21 trials are tracked, 1 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Emergency Medicine Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

GERD

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for GERD

21 trials tracked for GERD: 8 in phase 3 or 4 and 1 with published results. The most-cited published study has 262 citations.

21Trials tracked

8Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 4 4 Phase 3 4 Phase 2 2 Phase 1 2 Other / NA 9

Phase 3 A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors Completed · 262 cited
Phase 4 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed
Phase 4 Does Omeprazole Decrease Intestinal Calcium Absorption? Completed
Phase 4 The Utility of Nexium in Chronic Cough and Reflux Disease Completed
Phase 4 Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients Completed
Phase 3 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed

Show 15 more trials

Phase 3 Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD) Completed
Phase 3 Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients Completed
Phase 2 Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms Completed
Phase 2 Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma Completed
Phase 1 Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD: A Pilot Study Completed
Phase 1 Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects Completed
N/A Cytosponge Adequacy Study Evaluation II Completed
N/A Observational Study of Anti-Reflux Surgery Completed
N/A Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy Completed
N/A Correlates of GERD Symptom Severity Completed
N/A Complications, Outcomes and Revisions Following Hiatal Hernia Repair With MIROMESH Completed
N/A Physiology of GERD and Treatment Response Completed
N/A Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus Completed
N/A LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve Gastrectomy Completed
N/A Efficacy of Dx-pH Probe in Diagnosing Extra-esophageal Reflux Disease Completed

Showing the 21 most-cited and recently-updated of 21 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

GERD: what the trials found

Esomeprazole has demonstrated a significant reduction in the frequency of heartburn over an 8-week period (p<0.001) ¹. Clinical trials also indicate that esomeprazole is associated with changes in acid exposure time, specifically showing a decrease in the percentage of time with pH <4.0 and an increase in the percentage of time with pH between 4.0 and 6.9 ⁷.

While some studies evaluated symptomatic response to esomeprazole, results did not reach statistical significance (p=0.76) ⁶. Additionally, while maintenance treatment strategies for esomeprazole were assessed using the Gord Impact Scale (GIS), specific values for changes in scores were reported as 0.12, 0.04, and -0.22 ³.

Other pharmacological interventions include nizatidine; however, studies assessing its impact on GERD relief, severity, and success on the Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R) did not show statistically significant results (p=0.528 to 0.746) ⁸. Baclofen was also evaluated for improvements in the GERD Health-related Quality of Life Index (GERD-HRQL), with a small number of participants achieving at least a 50% improvement ⁵.

Recent results — preliminary, needs further review

linaprazan glurate 25 mg QD showed varying results for the percentage of time gastric pH >4 over a 24-hour monitoring period, though not yet corroborated ¹¹. Cytosponge was evaluated in several trials; however, findings regarding its impact on IES scores, VAS scores, and willingness to repeat are currently unconfirmed [13, 19]. A LINX device showed that 80.8% of participants reported a $\geq$50% reduction in GERD-HRQL score at 12 months, with 95.8% reporting a $\geq$50% reduction in daily PPI dosage ¹⁵. Amitriptyline was tested for GERD symptoms, but the change did not reach statistical significance (p=0.41) ¹⁴.

For the clinician treating this condition

Esomeprazole is effective in reducing heartburn frequency and altering acid exposure profiles [1, 7].
Nizatidine showed no statistically significant improvement in GERD relief or severity in the studied population ⁸.
Baclofen was shown to result in limited improvements in GERD-HRQL scores ⁵.

AI synthesis of 9 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.